AVI Biopharma (AVII) announces that it landed FDA approval to proceed with a modified dosing of...

|By:, SA News Editor

AVI Biopharma (AVII) announces that it landed FDA approval to proceed with a modified dosing of AVI-6003 for treatment of Marburg virus infections after positive testing of the drug on non-human primates. Shares +12.2% premarket.